<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03487913</url>
  </required_header>
  <id_info>
    <org_study_id>PA-102</org_study_id>
    <nct_id>NCT03487913</nct_id>
  </id_info>
  <brief_title>The ELiSA Study - Evaluation of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease</brief_title>
  <official_title>A Phase 2, Open-Label, Multi-Center Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Palladio Biosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Palladio Biosciences</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2, open-label, parallel-group, multiple dose study designed to evaluate the&#xD;
      pharmacokinetics, pharmacodynamics, safety and tolerability of multiple doses of lixivaptan&#xD;
      in Autosomal Dominant Polycystic Kidney Disease subjects with chronic kidney disease in&#xD;
      stages CKD1, CKD2 or CKD3.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Therapeutic interventions aimed at counterbalancing the effect of vasopressin and/or&#xD;
      normalizing intracellular levels of cAMP may be effective in delaying disease progression in&#xD;
      autosomal dominant polycystic kidney disease (ADPKD).&#xD;
&#xD;
      The primary objectives of this study in subjects with ADPKD are:&#xD;
&#xD;
        -  To characterize the safety and tolerability of lixivaptan following multiple doses in&#xD;
           ADPKD subjects with relatively preserved kidney function (chronic kidney disease CKD1&#xD;
           and CKD2) and moderately impaired renal function (CKD3).&#xD;
&#xD;
      The secondary objectives of this study are:&#xD;
&#xD;
        -  To characterize the PK profile of lixivaptan and its major metabolites following&#xD;
           multiple doses of lixivaptan in ADPKD subjects with relatively preserved kidney function&#xD;
           (CKD1 and CKD2) and moderately impaired renal function (CKD3).&#xD;
&#xD;
        -  To characterize the pharmacodynamic effect of lixivaptan on urine output, urine&#xD;
           osmolality, total kidney volume, serum vasopressin, and serum creatinine following&#xD;
           multiple doses of lixivaptan in ADPKD subjects with relatively preserved kidney function&#xD;
           (CKD1 and CKD2) and moderately impaired renal function (CKD3).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 14, 2018</start_date>
  <completion_date type="Actual">February 11, 2020</completion_date>
  <primary_completion_date type="Actual">December 2, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of study participants with treatment-emerging adverse events</measure>
    <time_frame>35 days</time_frame>
    <description>The number of study participants who experience treatment-emerging adverse events during the study will be measured.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the maximum observed plasma concentration of Lixivaptan in ADPKD patients</measure>
    <time_frame>10 days</time_frame>
    <description>The pharmacokinetic parameter Cmax will be used to measure the highest concentration of Lixivaptan in plasma after multiple doses of drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the area under the concentration-time curve from time 0 until the last quantifiable concentration of Lixivaptan in ADPKD patients</measure>
    <time_frame>10 days</time_frame>
    <description>The pharmacokinetic parameter AUC0-last for Lixivaptan, calculated using the linear trapezoidal rule for increasing values and the log trapezoidal rule for decreasing values, will be measured and summarized by dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in trough urine osmolality after 7 days of treatment with Lixivaptan in ADPKD patients</measure>
    <time_frame>7 days</time_frame>
    <description>Spot urine osmolality at trough (mOsm/kg) will be determined for urine samples collected immediately prior to morning dosing for Day 1 (Baseline) and Day 7.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in serum creatinine after 7 days of treatment with Lixivaptan in ADPKD patients</measure>
    <time_frame>7 days</time_frame>
    <description>Serum creatinine (mg/dL) will be determined from plasma samples collected immediately prior to morning dosing for Day 1 (Baseline) and Day 7.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Autosomal Dominant Polycystic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>High dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral lixivaptan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral lixivaptan</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lixivaptan</intervention_name>
    <description>Oral vasopressin V2 receptor antagonist</description>
    <arm_group_label>High dose</arm_group_label>
    <arm_group_label>Low dose</arm_group_label>
    <other_name>VPA-985</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female, between 18 and 65 years of age at the time of screening&#xD;
&#xD;
          -  Estimated glomerular filtration rate (eGFR) â‰¥ 30 mL/min/1.73 m2 with eGFR calculated&#xD;
             by the CKD EPI equation&#xD;
&#xD;
          -  Diagnosed with ADPKD by modified Ravine criteria&#xD;
&#xD;
          -  Considered by Investigator to be in good health relative to underlying CKD status and&#xD;
             clinically stable with respect to underlying CKD&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known sensitivity or idiosyncratic reaction to lixivaptan, its related compounds such&#xD;
             as benzazepines (e.g., tolvaptan, conivaptan, benazepril, fenoldopam, or mirtazapine),&#xD;
             or any compound listed as being present in the study formulation&#xD;
&#xD;
          -  Women who are pregnant or breast feeding&#xD;
&#xD;
          -  Subjects have taken tolvaptan, oral or intravenous antibiotics, or any investigational&#xD;
             drug or used an investigational device within 30 days or 5 half-lives, whichever is&#xD;
             longer, prior to first study dose&#xD;
&#xD;
          -  Subject has a transplanted kidney, or absence of a kidney&#xD;
&#xD;
          -  Subjects with clinically significant incontinence, overactive bladder, or urinary&#xD;
             retention (e.g., benign prostatic hyperplasia)&#xD;
&#xD;
          -  Subjects with clinically significant liver disease, or clinically significant liver&#xD;
             function abnormalities or serology other than that expected for ADPKD with cystic&#xD;
             liver disease at baseline&#xD;
&#xD;
          -  Subjects with any clinically significant concomitant disease or condition other than&#xD;
             ADPKD (including treatment for such conditions) that, in the opinion of the&#xD;
             Investigator, could either interfere with the study drug or pose an unacceptable risk&#xD;
             to the subject&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vicente E Torres, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Palladio Biosciences Clinical Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palladio Biosciences Clinical Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palladio Biosciences Clinical Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palladio Biosciences Clinical Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33165</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palladio Biosciences Clinical Site</name>
      <address>
        <city>Palmetto Bay</city>
        <state>Florida</state>
        <zip>33157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palladio Biosciences Clinical Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palladio Biosciences Clinical Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palladio Biosciences Clinical Site</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palladio Biosciences Clinical Site</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palladio Biosciences Clinical Site</name>
      <address>
        <city>Laurelton</city>
        <state>New York</state>
        <zip>11413</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palladio Biosciences Clinical Site</name>
      <address>
        <city>Indiana</city>
        <state>Pennsylvania</state>
        <zip>15701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palladio Biosciences Clinical Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palladio Biosciences Clinical Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>March 16, 2018</study_first_submitted>
  <study_first_submitted_qc>March 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2018</study_first_posted>
  <disposition_first_submitted>November 24, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>November 25, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">November 30, 2020</disposition_first_posted>
  <last_update_submitted>November 25, 2020</last_update_submitted>
  <last_update_submitted_qc>November 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthrogryposis</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Polycystic Kidney Diseases</mesh_term>
    <mesh_term>Polycystic Kidney, Autosomal Dominant</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

